First Patient Joins Tau NexGen Study in Early-onset Alzheimer’s

Home / Alzheimer's / First Patient Joins Tau NexGen Study in Early-onset Alzheimer’s
First Patient Joins Tau NexGen Study in Early-onset Alzheimer’s
January 31, 2022January 31, 2022
0

A first patient has joined the Tau NexGen study that will test two antibodies in combination — targeting both amyloid and tau proteins — as a potential treatment for early-onset Alzheimer’s disease caused by genetic mutations, according to a press release. Tau NexGen is a newly added arm of a Phase 2/3 platform trial, called DIAN-TU001 (NCT01760005), which is led by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), a network of researchers working around dominantly…

You must be logged in to read/download the full post.

The post First Patient Joins Tau NexGen Study in Early-onset Alzheimer’s appeared first on BioNewsFeeds.